#None #SAP-001 #Shanton Pharma #Refractory Gout

Shanton Pharma's Innovative Approach to Gout Treatment

Shanton Pharma, a clinical-stage biotech company, has released exciting topline data from their Phase 2b clinical trial targeting patients with refractory gout. The investigational drug, SAP-001, is developed with a novel mechanism that specifically targets a unique kidney transporter. The findings indicate a significant potential to treat patients who have not responded to conventional therapies.

Dr. Bing Li, CEO of Shanton Pharma, expressed enthusiasm regarding the outcomes of the trial, conducted on 87 refractory gout patients across 21 U.S. sites. Notably, the study aimed to assess the efficacy and safety of SAP-001 dosages of 10 mg, 30 mg, and 60 mg. By the end of the third month, nearly all patients receiving 30 mg and 60 mg dosages reached their therapeutic targets of serum uric acid levels falling below 6 mg/dL. In contrast, only about 10% of those on conventional treatments achieved the same result.

During the six-month treatment period, these remarkable effects persisted, with over 50% of patients on the 60 mg dose managing to lower their uric acid levels even further, dropping below 3 mg/dL. Dr. Wenfeng Miao, Chief Medical Officer of Shanton, highlighted that this is the first clinical study demonstrating successful oral drug treatment for refractory gout patients, who typically require intravenous therapies like uricase.

Gout, known as the most common form of inflammatory arthritis, afflicts over 12 million adults in the United States. It occurs when excessive uric acid in the bloodstream leads to painful attacks and, if untreated, can result in severe joint damage. Despite various urate-lowering therapies available, approximately 29% of diagnosed patients are receiving appropriate treatment, with only half responding adequately to existing medications. Tragically, an estimated 20% of patients on standard care options remain refractory.

Shanton's trial's promising results signal a potential shift in how refractory gout is managed. The company's pioneering approach in focusing on a new mechanism of action to lower uric acid levels addresses long-standing unmet needs in the medical community. As they prepare for pivotal studies later this year, the expectation is that SAP-001 could usher in a new era of gout management, making a substantial difference in patients' lives.

Shanton, founded in 2016 and headquartered in Singapore, is dedicated to developing groundbreaking treatments aimed at addressing unmet medical needs related to hyperuricemia and gout. With SAP-001 already demonstrating compelling efficacy and safety profiles in previous Phase 1 and 2a clinical studies, the ongoing research aims to refine this drug for widespread clinical use.

For more information on Shanton Pharma, visit their official website at shantonpharma.com.